Ribomic said 18 children had been registered in its domestic phase III trial of umedaptanib pegol for achondroplasia as of 17 November, two more than the 16 the study planned. The company announced the milestone in a TDnet notice.
Recruitment ahead of plan, count not final
The study, called WAKABA, enrolls patients aged 2 to 14 with achondroplasia. Registration began in July 2026 with the first subject, and sites across Japan have been enrolling since.
The consent window ran to the end of October. Ribomic plans to register, by the end of November, those who gave consent in that window, so the final count may reach a maximum of 25. The 18 is therefore a running figure, not a fixed one. Ribomic says the extra patients should yield more clinical data than originally planned for assessing efficacy and safety.
What the trial still has to show
Filling the roster is not a result. Ribomic's March 2026 trial-application notice set the primary endpoint as the change in annualized height velocity after 52 weeks of dosing, measured against the pre-treatment observation period. The dose is 1 mg/kg by weekly subcutaneous injection. The planned trial period is 78 weeks, with 26 weeks of observation and 52 weeks of dosing.
The design is multicentre, non-randomized, open-label and single-arm, with no placebo group. In a July 2026 explanatory note, Ribomic said a placebo control could mean long periods without treatment for growing children, a medical and ethical burden that could also make recruitment harder and lengthen the study. It said the pre- and post-dosing comparison of height velocity lets it assess the drug's effect directly.
The appendix to that note gives the planned study period as May 2026 to April 2028. Efficacy and safety data from the 52-week dosing period therefore lie ahead, and the notice reports no clinical results. Ribomic says it will keep running the trial toward an early approval.
Background and financial effect
Umedaptanib pegol, the international name for RBM-007, is an aptamer (a nucleic-acid drug) that inhibits fibroblast growth factor 2. It has orphan drug designation from Japan's health ministry. Achondroplasia, caused by a mutation in the FGFR3 gene, occurs in about one in 25,000 newborns, according to the company.
Ribomic said the effect on results for the year ending March 2027 is minor.
